Treatment of <i>Enterococcus faecalis</i> infective endocarditis with penicillin G plus ceftriaxone

Suzuki, Hiroyuki; Carlson, Jennifer R; Matsumoto, Eiyu

doi:10.1080/23744235.2019.1672888

Cited by 12 publications

(20 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As shown in Table 1 , the study designs of the 18 selected articles included randomized clinical trials ( n = 1) [ 12 ], non-randomized clinical trials ( n = 1) [ 26 ], prospective cohort studies ( n = 2) [ 27 , 28 ], retrospective cohort studies ( n = 9) [ 20 , 22 , 23 , 29 , 30 , 31 , 32 , 33 , 34 ] and case series studies ( n = 5) [ 19 , 21 , 24 , 25 , 35 ]. Only 10 of them analyzed more than one treatment option [ 12 , 20 , 23 , 27 , 28 , 29 , 30 , 31 , 32 , 33 ].…”

Section: Resultsmentioning

confidence: 99%

“…Only 10 of them analyzed more than one treatment option [ 12 , 20 , 23 , 27 , 28 , 29 , 30 , 31 , 32 , 33 ]. The study clinical settings were outpatient ( n = 4) [ 19 , 24 , 25 , 34 ], inpatient ( n = 9) [ 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 35 ] and mixed ( n = 5) [ 12 , 20 , 21 , 22 , 23 ], and the therapy indication included continuation therapy in nine studies [ 12 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 34 ]. The majority of studies included left- and right-sided endocarditis, with the exception of three studies treating only left-sided IE [ 12 , 28 , 33 ].…”

Section: Resultsmentioning

confidence: 99%

“…There were large variations regarding the follow-up period after the ending of the antimicrobial therapy, ranging between no follow-up [ 20 ] and one year after [ 29 , 30 , 33 , 34 ]. Mortality was the most common outcome measure, being described in all articles, while relapse incidences were reported in 13 studies [ 12 , 19 , 22 , 23 , 24 , 25 , 26 , 27 , 29 , 30 , 31 , 33 , 34 ] and treatment failure in only 11 studies [ 12 , 19 , 20 , 21 , 22 , 25 , 27 , 29 , 30 , 31 , 32 ]. Two articles presented data from the same study population; nevertheless, both were included because different aims and outcomes were assessed [ 26 , 27 ].…”

Section: Resultsmentioning

confidence: 99%

“…Nine studies gathered clinical results about 337 E. faecalis IE episodes treated with dual β-lactam therapy [ 19 , 20 , 24 , 25 , 26 , 27 , 29 , 30 , 31 ], three of which were conducted in OPAT, and then collected data from 11 patients [ 19 , 24 , 25 ]. The follow-up comprised six months ( n = 6), three months ( n = 1), and another study referred no follow-up after treatment ending.…”

Section: Resultsmentioning

confidence: 99%

“…E. faecalis IE treatment via OPAT has not been usually recommended [ 10 , 14 , 15 , 16 , 17 ], and sometimes even discouraged [ 11 , 18 ]. Nevertheless, evidence supporting E. faecalis IE continuation treatment through OPAT has grown lately, including a variety of antibiotic options, with favorable results [ 19 , 20 , 21 , 22 , 23 , 24 , 25 ].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Enterococcus faecalis Endocarditis and Outpatient Treatment: A Systematic Review of Current Alternatives

et al. 2020

View full text Add to dashboard Cite

The selection of the best alternative for Enterococcus faecalis infective endocarditis (IE) continuation treatment in the outpatient setting is still challenging. Three databases were searched, reporting antibiotic therapies against E. faecalis IE in or suitable for the outpatient setting. Articles the results of which were identified by species and treatment regimen were included. The quality of the studies was assessed accordingly with the study design. Data were extracted and synthesized narratively. In total, 18 studies were included. The treatment regimens reported were classified regarding the main antibiotic used as regimen, based on Aminoglycosides, dual β-lactam, teicoplanin, daptomycin or dalbavancin or oral therapy. The regimens based on aminoglycosides and dual β-lactam combinations are the treatment alternatives which gather more evidence regarding their efficacy. Dual β-lactam is the preferred option for high level aminoglycoside resistance strains, and for to its reduced nephrotoxicity, while its adaptation to the outpatient setting has been poorly documented. Less evidence supports the remaining alternatives, but many of them have been successfully adapted to outpatient care. Teicoplanin and dalbavancin as well as oral therapy seem promising. Our work provides an extensive examination of the potential alternatives to E. faecalis IE useful for outpatient care. However, the insufficient evidence hampers the attempt to give a general recommendation.

show abstract